A detailed history of Dodge & Cox transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dodge & Cox holds 1,280,820 shares of NBIX stock, worth $163 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,280,820
Previous 1,265,244 1.23%
Holding current value
$163 Million
Previous $175 Million 1.05%
% of portfolio
0.11%
Previous 0.11%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $2.04 Million - $2.23 Million
15,576 Added 1.23%
1,280,820 $176 Million
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $717,200 - $790,570
5,500 Added 0.44%
1,265,244 $175 Million
Q4 2023

Feb 15, 2024

BUY
$106.07 - $132.76 $111 Million - $139 Million
1,046,142 Added 489.76%
1,259,744 $166 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $20.1 Million - $25 Million
213,602 New
213,602 $24 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Dodge & Cox Portfolio

Follow Dodge & Cox and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.